Formation of the hepatitis delta virion relies on prenylation, a post-translational modification that can be inhibited using lonafarnib. In a phase IIA double-blind, randomized, placebo-controlled study, 14 patients with chronic HDV infection received different concentrations of the inhibitor or placebo, and a dose-dependent reduction in virus levels was evident in treatment groups. Adverse events were mild to moderate.